1 |
Angus DC, van der Poll T. Severe sepsis and septic shock[J]. N Engl J Med, 2013, 369 (9): 840-851.
|
2 |
Song T, Yin H, Chen J, et al. Survival advantage depends on cecal volume rather than cecal length in a mouse model of cecal ligation and puncture[J]. J Surg Res, 2016, 203 (2): 476-482.
|
3 |
Torpy JM, Lynm C, Glass RM. JAMA patient page. Intensive care units[J]. JAMA, 2009, 301 (12): 1304.
|
4 |
Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care[J]. Crit Care Med, 2001, 29 (7): 1303-1310.
|
5 |
Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study[J]. Crit Care Med, 2006, 34 (2): 344-353.
|
6 |
Esper AM, Moss M, Lewis CA, et al. The role of infection and comorbidity: factors that influence disparities in sepsis[J]. Crit Care Med, 2006, 34 (10): 2576-2582.
|
7 |
Cavaillon JM, Adib-Conquy M, Fitting C, et al. Cytokine cascade in sepsis[J]. Scand J Infect Dis, 2003, 35 (9): 535-544.
|
8 |
Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, et al. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding[J]. Physiol Rev, 2013, 93 (3): 1247-1288.
|
9 |
Zhou J, Qian C, Zhao M, et al. Epidemiology and outcome of severe sepsis and septic shock in intensive care units in mainland China[J]. PloS One, 2014, 9 (9): e107181.
|
10 |
Gaieski DF, Edwards JM, Kallan MJ, et al. Benchmarking the incidence and mortality of severe sepsis in the United States[J]. Crit Care Med, 2013, 41 (5): 1167-1174.
|
11 |
Clark JA, Coopersmith CM. Intestinal crosstalk: a new paradigm for understanding the gut as the "motor" of critical illness[J]. Shock, 2007, 28 (4): 384-393.
|
12 |
Dominguez JA, Coopersmith CM. Can we protect the gut in critical illness? The role of growth factors and other novel approaches[J]. Crit Care Clin, 2010, 26 (3): 549-565, x.
|
13 |
Hassoun HT, Kone BC, Mercer DW, et al. Post-injury multiple organ failure: the role of the gut[J]. Shock, 2001, 15 (1): 1-10.
|
14 |
Sartor RB. Probiotic therapy of intestinal inflammation and infections[J]. Curr Opin Gastroenterol, 2005, 21 (1): 44-50.
|
15 |
Weber GF, Schlautkotter S, Kaiser-Moore S, et al. Inhibition of interleukin-22 attenuates bacterial load and organ failure during acute polymicrobial sepsis[J]. Infect Immun, 2007, 75 (4): 1690-1697.
|
16 |
Rittirsch D, Huber-Lang MS, Flierl MA, et al. Immunodesign of experimental sepsis by cecal ligation and puncture[J]. Nat Protoc, 2009, 4 (1): 31-36.
|
17 |
Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000[J]. N Engl J Med, 2003, 348 (16): 1546-1554.
|
18 |
Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis[J]. Virulence, 2014, 5 (1): 4-11.
|
19 |
归崎峰,杨云梅,张家嘉. 他汀类药物对中国老年脓毒症患者住院期间病死率的影响[J/CD]. 中华危重症医学杂志(电子版),2016,9(1):34-37.
|
20 |
Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units[J]. JAMA, 2009, 302 (21): 2323-2329.
|
21 |
MacFie J. Current status of bacterial translocation as a cause of surgical sepsis[J]. Brit Med Bull, 2004 (71): 1-11.
|
22 |
Power SE, O'Toole PW, Stanton C, et al. Intestinal microbiota, diet and health[J]. Br J Nutr, 2014, 111 (3): 387-402.
|
23 |
Schroder J, Wardelmann E, Winkler W, et al. Glutamine dipeptide-supplemented parenteral-nutrition reverses gut atrophy, disaccharidase enzyme-activity, and absorption in rats[J]. JPEN J Parenter Enteral Nutr, 1995, 19 (6): 502-506.
|
24 |
Roland CR, Goss JA, Mangino MJ, et al. Autoregulation by eicosanoids of human kupffer cell secretory products - a study of interleukin-1, interleukin-6, tumor-necrosis-factor-alpha, transforming growth-factor-beta, and nitric-oxide[J]. Ann Surg, 1994, 219 (4): 389-399.
|
25 |
Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis[J]. Am J Gastroenterol, 2014, 109 (10): 1547-1561.
|
26 |
Shen J, Zuo ZX, Mao AP. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, crohn's disease, and pouchitis: meta-analysis of randomized controlled trials[J]. Inflamm Bowel Dis, 2014, 20 (1): 21-35.
|
27 |
Deshpande G, Rao S, Patole S, et al. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates[J]. Pediatrics, 2010, 125 (5): 921-930.
|
28 |
Parkes GC, Sanderson JD, Whelan K. The mechanisms and efficacy of probiotics in the prevention of clostridium difficile-associated diarrhoea[J]. Lancet Infect Dis, 2009, 9 (4): 237-244.
|
29 |
Guarino A, Guandalini S, Lo Vecchio A. Probiotics for prevention and treatment of diarrhea[J]. J Clin Gastroenterol, 2015, 49 Suppl 1: S37-S45.
|
30 |
曹超,柴艳芬,寿松涛,等. 乌司他丁对脓毒症小鼠调节性T细胞凋亡及细胞因子分泌的影响[J/CD]. 中华危重症医学杂志(电子版),2017,10(3):149-152.
|
31 |
Mennigen R, Nolte K, Rijcken E, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis[J]. Am J Physiol Gastrointest Liver Physiol, 2009, 296 (5): G1140-G1149.
|
32 |
Lichtman SM. Bacterial [correction of baterial] translocation in humans[J]. J Pediatr Gastroenterol Nutr, 2001, 33 (1): 1-10.
|